Drug cost distribution by type in select public drug plans Canada 2020/2021

Patented drugs had a share of some 56 percent of drug costs in select public Canadian drug plans. This statistic depicts the distribution of drug costs by drug type in select Canadian public drug plans in Canada as of fiscal year 2020/2021.

Distribution of drug costs by drug type in select public Canadian drug plans in 2020/2021

Drug type	Share of drug cost
Patented*	56.4%
Multi-source non-patented: generic	17.2%
Multi-source non-patented: non-generic	13%
Single-source non-patented	8.6%
Other**	4.7%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

2023

More information

Region

Canada

Survey time period

fiscal year 2020/2021

Supplementary notes

This analysis only includes data for beneficiaries that met their deductible and received public reimbursement. Direct-acting antiviral (DAA) drugs are used in the treatment of hepatitis C. High-cost drugs have an average annual treatment cost of greater than $10,000 and include both biologics and non-biologics.
Included are: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and Yukon.
* The patented medicines market segment includes all medicines that had patent protect at some time during in the period of study, even if the patent expired during that period. As such, the rate of growth does not reflect the loss of patent exclusivity for some top-selling medicines over the course of the fiscal year.
** This market segment includes devices, compounded drugs, and other products that are reimbursed by public drug plans but do not have a Health Canada assigned Drug Identification Number (DIN).

Citation formats